++
For patients with multiagent refractory disease, CAR T-cell therapy targeting the early plasma cell antigen BCMA has shown response rates exceeding 70% and median duration of response of over 11 months.
++
van de Donk NWCJ et al. Lancet Haematol. [PMID: 34048683]